Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, shared on LinkedIn:
“What happens to patients with EGFR–mutant lung cancer after first-line osimertinib stops working? The FLAURA2 trial established that adding chemotherapy to osimertinib improves overall survival in metastatic EGFR-mutant NSCLC.
But one important question remains: how much of that benefit is influenced by what happens after first-line therapy?
A retrospective study of 115 patients treated with first-line osimertinib monotherapy at a U.S. academic medical center offers a sobering real-world perspective.
Among the 66 patients who discontinued osimertinib:
- 40 experienced disease progression
- Only 40/66 (61%) received second-line therapy
- 26 patients (39%) died or pursued hospiceIn other words, nearly 4 in 10 patients who discontinued first-line osimertinib never reached another systemic treatment.
The study also highlights the heterogeneity of EGFR-mutant disease.
Median time to treatment failure was:25.3 months overallBut only 15.7 months for patients with TP53-mutant tumors versus 42.2 months for TP53 wild-type disease.
That difference raises an important question about treatment strategy: If a substantial proportion of patients never receive second-line therapy, should we be thinking differently about how much treatment to deliver upfront?
The findings are strikingly similar to the FLAURA2 control arm, where only about 60% of patients received subsequent therapy.
This is an important reminder that overall survival is shaped not only by the efficacy of first-line therapy, but by the entire treatment journey-including whether patients are able to reach and tolerate subsequent lines.
The challenge now is identifying which patients are likely to benefit from treatment intensification upfront versus those who may derive sufficient benefit from osimertinib alone.
Real-world treatment patterns can reveal something clinical trials sometimes cannot: what actually happens between progression and the next treatment.”
You can also read: FLAURA2 Long-Term Safety: Toxicity Peaks Early With Osimertinib Plus Chemotherapy and Declines Over Time.
